Navigation Links
FDA Approves GlaxoSmithKline's AVODART(R) in Combination with Tamsulosin for the Treatment of Symptomatic Enlarged Prostate
Date:6/19/2008

n was superior to both monotherapies at Month 12 and continued to Month 24. The primary endpoint was the change in International Prostate Symptom Score (IPSS) from baseline at Month 24 for combination therapy compared to each medication alone. The most common adverse reactions reported in subjects receiving combination therapy were impotence, decreased libido, breast disorders (including breast enlargement and tenderness), ejaculation disorders, and dizziness.

Data from the remaining 2 years of the CombAT study will provide further information on the pattern of symptoms and long-term outcomes associated with combination therapy vs. AVODART and tamsulosin monotherapies.

About CombAT

CombAT is a multicenter, randomized, double-blind and parallel-group study. Men [aged greater than or equal to 50 years with a prostate volume (PV) greater than or equal to 30 cc, serum prostate-specific antigen (PSA) level 1.5-10 ng/mL, Qmax >5 and less than or equal to 15 mL/sec with a minimum voided volume greater than or equal to 125 mL and International Prostate Symptom Score (IPSS) greater than or equal to 12] with moderate-to-severe enlarged prostate symptoms received placebo for four weeks and were then randomized to receive AVODART 0.5 mg/day and tamsulosin 0.4 mg/day (n=1610), AVODART 0.5 mg/day (n=1623), or tamsulosin 0.4 mg/day (n=1611).

ABOUT AVODART

AVODART, the first and only dual 5ARI for the treatment of enlarged prostate, inhibits both the type I and type II isoenzymes responsible for the conversion of testosterone into dihydrotestosterone (DHT). DHT is the primary male hormone responsible for the enlargement of the prostate. AVODART suppresses DHT by 93 percent at 2 years. AVODART is indicated for the treatment of symptomatic enlarged prostate in men with an enlarged prostate to improve symptoms, reduce the risk of acute urinary retention (AUR), and reduce the risk of prostate-related surgery. AVODART is now indicated in combination wi
'/>"/>

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
2. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
3. FDA Approves VYVANSE(TM) (lisdexamfetamine dimesylate), the First and Only Once-Daily Prodrug Stimulant to Treat ADHD in Adults
4. Maryland Approves Medicaid Reimbursement for ActiPatch(R)
5. Healthcare Coalition Approves Tools to Improve Patient Safety During Transitions of Care
6. Medicare Approves in Home Sleep Apnea Testing
7. 3SBio Inc. Approves Share Repurchase Program
8. Baxters Board of Directors Approves New Share Repurchase Authorization of $2 Billion
9. FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder
10. FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy
11. FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE(TM) (lisdexamfetamine dimesylate) Which May Help Physicians Tailor Treatment for Individual Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... , July 10, 2014 On ... Dmitry Medvedev , presented Russia,s ... BIOCAD . The Company is developing a unique project ... project BIOCAD develops a number of innovative drugs based ... diseases. The ceremony took place at the International Exhibition ...
(Date:7/10/2014)... 2014 /PRNewswire-iReach/ -- Tute Genomics, the leader ... an agreement with Lineagen, Inc., to provide ... Dx PLUS.  Lineagen, focused on the ... currently offers FirstStep Dx PLUS, a ... by healthcare providers as a first-line genetic ...
(Date:7/10/2014)... THOUSAND OAKS, Calif., July 10, 2014   Ceres, ... biotechnology and seed company, announced today financial results for ... an update on its business. Ceres reported ... progress in product performance this growing season in Brazil, ... that affected the company,s sorghum evaluation areas for part ...
(Date:7/10/2014)... Adelaide research may help in the fight against terrorism ... tiny quantities of explosives with the use of light ... Sensors and Actuators B: Chemical , the researchers ... explosives in concentrations as low as 6.3 ppm (parts ... a few minutes. , "Traditionally explosives detection has involved ...
Breaking Biology Technology:Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Detecting trace amounts of explosives with light 2
... oncology intelligence initiative powered by The Arcas Group, announced ... following this month,s annual meeting of the American Society ... expand on previous Quick Polls carried out after the ... efforts after the American Society of Hematology (ASH) annual ...
... Incorporated (NASDAQ: SPEX ) -- an ... syndrome and atherosclerosis, and providers of technical and ... pharmaceutical companies -- today announced that its Annual ... will be held on Tuesday, November 15, 2011, ...
... 2011 ,   ... that its,US-subsidiary NextGen Sciences Inc, a leader in ... cerebrospinal,fluid (CSF) multiple protein (multiplex) assay, csf ... qualification . The assay simultaneously measures,43 human CSF ...
Cached Biology Technology:MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 2MDOUTLOOK® 4th Annual Quick Polls From ASCO 2011: Report on Clinical Impact of New Developments in Cancer Therapeutics 3Spherix Announces Annual Shareholders Meeting Date 2NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay 2NextGen Sciences Launches Multiple Protein cerebrospinal fluid (CSF) CNS Disease Biomarker Assay 3
(Date:7/11/2014)... is evidence that under the normal circumstances, ... development, maintain neuronal environment, and exhibit therapeutic ... neurodegenerative disease. Previous studies have found that ... after chemical induction have reduced viability, which ... Prof. Xiaodong Yuan, Kailuan General Hospital, Hebei ...
(Date:7/10/2014)... Fe, Albuquerque, and other major cities in New Mexico, ... treated municipal wastewater rather than precious potable water supplies. ... 40% of all golf courses receive treated effluent. Reusing ... , Additionally, golf courses and homeowners alike fertilize their ... fertilizer is nitrate. A New Mexico State University turfgrass ...
(Date:7/10/2014)... 2014  Unisys Corporation,s (NYSE: UIS ) subsidiary ... today announced that it has been selected by the Dutch ... new Basic Provision Biometrics solution for penitentiaries across ... contract with a solution based on its open standards-based ... the contract is up to seven years, with the new ...
Breaking Biology News(10 mins):'Tailored' water -- the latest in lawn care 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
... in the online edition of Physiological Genomics finds that individuals ... The study offers the first evidence of the role that ... controls sugar entry into the cells has on sugar ... in sugar. The study was conducted by Ahmed ...
... to Critical Data with MobileCop(R) ... ... International Inc.,(OTC Bulletin Board: BKYI), a leader in finger-based biometric,identification and ... Baltimore (MD) Police Department ("BPD"),for additional licenses of BIO-key,s MobileCop software ...
... new ways to stop the progression of cancer, researchers ... discovered a compound that has shown to prevent cancer ... Gene Regulation and Systems Biology. The compound, which ... normal cells from turning into cancer cells and inhibited ...
Cached Biology News:Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 2BIO-key(R) Receives $335,000 Contract Award From Baltimore Police 3Chemical compound prevents cancer in lab 2
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
Src cDNA Expression Kit (wild type)...
1M stock solution (238mg/ml)...
Homogenizing Solution, 18ml Proteinase K - [50ug/l] 75 l...
Biology Products: